The effects of promoter methylation on downregulation of dazap2 in multiple myeloma cell lines

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Luo, Sai Qun ^a   Hu, Jing Ping ^a   Qu, Qiang ^a   Li, Jiang ^a   Ren, Wei ^a   Zhang, Jia Ming ^a   Zhong, Yan ^a   Hu, Wei Xin ^a  

^a Central South University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; CPG ISLAND; DAZAP2 GENE; DNA DENATURATION; DNA METHYLATION; DOWN REGULATION; ENZYME ACTIVITY; EPIGENETICS; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE SEQUENCE; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; MULTIPLE MYELOMA; MYELOMA CELL; NUCLEOTIDE SEQUENCE; PLASMID; PROMOTER REGION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; AZACITIDINE; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; RNA-BINDING PROTEINS; SEQUENCE ANALYSIS, DNA; TRANSCRIPTION, GENETIC;

EID: 84863621028     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040475     Document Type: Article

References (41)

1. Hallek M, Bergsagel PL, Anderson KC, (1998) Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91: 3-21.
2. Kuehl WM, Bergsagel PL, (2002) Multiple myeloma: evolving genetic events and host interactions. Nature Reviews Cancer 2: 175-187.
3. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, et al. (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood 87: 1104-1112.
4. Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ, et al. (2006) A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 24: 986-991.
5. Raje N, Kumar S, Hideshima T, Roccaro A, Ishitsuka K, et al. (2005) Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 106: 1042-1047.
6. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, et al. (2004) Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5: 221-230.
7. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, et al. (2006) Antimyeloma activity of heat shock protein-90 inhibition. Blood 107: 1092-1100.
8. Choi SJ, Oba Y, Gazitt Y, Alsina M, Cruz J, et al. (2001) Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease. J Clin Invest 108: 1833-1841.
9. Tian E, Zhan FH, Walker R, Rasmussen E, Ma YP, et al. (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349: 2483-2494.
10. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC, (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nature Reviews Cancer 7: 585-598.
11. Mateos MV, Garcia-Sanz R, Lopez-Perez R, Moro MJ, Ocio E, et al. (2002) Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol 118: 1034-1040.
12. Kocemba KA, Groen RWJ, van Andel H, Kersten MJ, Mahtouk K, et al. (2012) Transcriptional Silencing of the Wnt-Antagonist DKK1 by Promoter Methylation Is Associated with Enhanced Wnt Signaling in Advanced Multiple Myeloma. PLoS One 7(2): e30359.
13. Shaughnessy J, Tian E, Sawyer J, Bumm K, Landes R, et al. (2000) High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 96: 1505-1511.
14. Sossey-Alaoui K, Kitamura E, Head K, Cowell JK, (2002) Characterization of FAM10A4, a member of the ST13 tumor suppressor gene family that maps to the 13q14.3 region associated with B-Cell leukemia, multiple myeloma, and prostate cancer. Genomics 80: 5-7.
15. Kulkarni MS, Daggett JL, Bender TP, Kuehl WM, Bergsagel PL, et al. (2002) Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis. Leukemia 16: 127-134.
16. Klein B, Zhang XG, Lu ZY, Bataille R, (1995) Interleukin-6 in human multiple myeloma. Blood 85: 863-872.
17. Dewan MZ, Watanabe M, Terashima K, Aoki M, Sata T, et al. (2004) Prompt tumor formation and maintenance of constitutive NF-kappaB activity of multiple myeloma cells in NOD/SCID/gammacnull mice. Cancer Sci 95: 564-568.
18. Anderson KC, Shaughnessy JD Jr, Barlogie B, Harousseau JL, Roodman GD, (2002) Multiple myeloma. Hematology 1: 214-240.
19. Wang MC, Fu XD, Li MX, (2006) PI-3K/Akt/GSK-3β signaling cascades stimulated by insulin like growth factor-I contribute to multiple myeloma cells proliferation and survival. Chin Med J 119: 1226-1229.
20. Liu H, Wang J, Epner EM, (2004) Cyclin D1 activation in B-cell malignancy: association with changes in histone acetylation, DNA methylation, and RNA polymerase II binding to both promoter and distal sequences. Blood 104: 2505-2513.
21. Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IM, (2005) Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 105: 317-323.
22. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC, (2004) Advances in biology of multiple myeloma: clinical applications. Blood 104: 607-618.
23. Tsui S, Dai T, Roettger S, Schempp W, Salido EC, et al. (2000) Identification of two novel proteins that interact with germ-cell-specific RNA-binding proteins DAZ and DAZL1. Genomics 65: 266-273.
24. Lukas J, Mazna P, Valenta T, Doubravska L, Pospichalova V, et al. (2009) Dazap2 modulates transcription driven by the Wnt effector TCF-4. Nucleic Acids Research 37: 3007-3020.
25. Roche DD, Liu KJ, Harland RM, Monsoro-Burq AH, (2009) Dazap2 is required for FGF-mediated posterior neural patterning, independent of Wnt and Cdx function. Developmental Biology 333: 26-36.
26. Shi YW, Luo SQ, Peng JB, Huang CH, Tan DR, et al. (2004) The Structure, Expression and Function Prediction of DAZAP2, A Down-Regulated Gene in Multiple Myeloma. Gen Prot Bioinfo 2: 47-54.
27. Shi YW, Shen R, Ren W, Tang LJ, Tan DR, et al. (2007) The molecular features and expression of DAZAP2 in human multiple myeloma. Chin Med J 120: 1659-1665.
28. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, et al. (2006) The molecular classification of multiple myeloma. Blood 108: 2020-2028.
29. Choi SH, Heo K, Byun HM, An WJ, Lu WG, et al. (2011) Identification of preferential target sites for human DNA methyltransferases. Nucleic Acids Research 39: 104-118.
30. Dejeux E, Rønneberg JA, Solvang H, Bukholm I, Geisler S, et al. (2010) DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol Cancer 9: 68.
31. Corn PG, Kuerbitz SJ, van Noesel MM, Esteller M, Compitello N, et al. (1999) Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation. Cancer Res 59: 3352-3356.
32. Feinberg AP, Tycko B, (2004) Timeline- The history of cancer epigenetics. Nature Reviews Cancer 4: 143-153.
33. Siu LLP, Chan JK, Wong KF, Choy C, Kwong YL, (2003) Aberrant promoter CpG methylation as a molecular marker for disease monitoring in natural killer cell lymphomas. Br J Haematol 122: 70-77.
34. Pei JH, Luo SQ, Zhong Y, Chen JH, Xiao HW, et al. (2011) The association between non-Hodgkin lymphoma and methylation of p73. Tumor Biology 32: 1133-1138.
35. Galm O, Wilop S, Luders C, Jost E, Gehbauer G, et al. (2005) Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia. Annals of Hematology pp. 39-46.
36. Roman-Gomez J, Agirre X, Jiménez-Velasco A, Arqueros V, Vilas-Zornoza A, et al. (2009) Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. J Clin Oncol 27: 1316-1322.
37. Chiam K, Centenera MM, Butler LM, Tilley WD, Bianco-Miotto T, (2011) GSTP1 DNA methylation and expression status is indicative of 5-aza-2′-deoxycytidine efficacy in human prostate cancer cells. PLoS One 6(9): e25634.
38. Schmelz K, Wagner M, Dörken B, Tamm I, (2005) 5-Aza-2′-deoxycytidine induce p21(WAF) express by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Cancer 114: 683-695.
39. Wijermans PW, Lübbert M, Verhoef G, Klimek V, Bosly A, (2005) An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients. Ann Hematol pp. 9-17.
40. Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, et al. (2006) DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res 66: 5495-5503.
41. Link PA, Baer MR, James SR, Jones DA, Karpf AR, (2008) p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. Cancer Res 68: 9358-9366.